Ombitasvir/paritaprevir/ritonavir

Drug Profile

Ombitasvir/paritaprevir/ritonavir

Alternative Names: ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); VIEKIRA XR; Viekirax

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Amides; Anilides; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Cyclopropanes; Phenanthridines; Pyrroles; Pyrrolidines; Small molecules; Sulfones; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Mar 2017 AbbVie completes the phase III TURQUOISE-CPB trial in Hepatitis C (Combination therapy) in Germany, Canada and USA (NCT02219477)
  • 28 Feb 2017 Abbvie completes the phase III CERTAIN-1 trial in Hepatitis C in Japan (NCT02707952)
  • 27 Feb 2017 CHMP of the EMA grants a positive opinion for the eight-week treatment option with ombitasvir/paritaprevir/ritonavir tablets in combination with dasabuvir tablets for Chronic hepatitis C virus infected genotype 1b (GT1b) patients with moderate fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top